Cullinan Therapeutics to Participate in Upcoming Investor Conferences
Cullinan Therapeutics (Nasdaq: CGEM), a biopharmaceutical company specializing in modality-agnostic targeted therapies, has announced its participation in two upcoming investor conferences. CEO Nadim Ahmed and CMO Jeffrey Jones will present at the Cantor Global Healthcare Conference on September 4, 2025, at 2:10 p.m. ET, and at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10, 2025, at 8:30 a.m. ET.
Both presentations will be available as webcasts through Cullinan's investor relations website.
Cullinan Therapeutics (Nasdaq: CGEM), una societ脿 biofarmaceutica specializzata in terapie mirate indipendenti dalla modalit脿, ha annunciato la propria partecipazione a due prossimi convegni per investitori. Il CEO Nadim Ahmed e il CMO Jeffrey Jones interverranno al Cantor Global Healthcare Conference il 4 settembre 2025 alle 14:10 ET e al Morgan Stanley 23rd Annual Global Healthcare Conference il 10 settembre 2025 alle 8:30 ET.
Entrambe le presentazioni saranno disponibili in webcast sul sito delle relazioni con gli investitori di Cullinan.
Cullinan Therapeutics (Nasdaq: CGEM), una compa帽铆a biofarmac茅utica especializada en terapias dirigidas independientes de la modalidad, ha anunciado su participaci贸n en dos pr贸ximas conferencias para inversores. El CEO Nadim Ahmed y el CMO Jeffrey Jones presentar谩n en el Cantor Global Healthcare Conference el 4 de septiembre de 2025 a las 14:10 ET y en el Morgan Stanley 23rd Annual Global Healthcare Conference el 10 de septiembre de 2025 a las 8:30 ET.
Ambas presentaciones estar谩n disponibles en webcast a trav茅s del sitio web de relaciones con inversores de Cullinan.
Cullinan Therapeutics (Nasdaq: CGEM)電� 氇嫭毽嫲鞐� 甑暊氚涭 鞎婋姅 響滌爜 旃橂鞝滊ゼ 鞝勲鞙茧 頃橂姅 氚旍澊鞓れ牅鞎巾殞靷, 雼り皜鞓る姅 霊� 瓯挫潣 韴瀽鞛� 旎嵓霟办姢鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. CEO Nadim Ahmed鞕� CMO Jeffrey Jones電� Cantor Global Healthcare Conference鞐� 2025雲� 9鞗� 4鞚� 鞓ろ泟 2鞁� 10攵�(ET)鞐�, Morgan Stanley 23rd Annual Global Healthcare Conference鞐� 2025雲� 9鞗� 10鞚� 鞓れ爠 8鞁� 30攵�(ET)鞐� 氚滍憸頃� 鞓堨爼鞛呺媹雼�.
霊� 氚滍憸 氇憪 Cullinan鞚� 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼毳� 韱淀暣 鞗轨簮鞀ろ姼搿� 鞝滉车霅╇媹雼�.
Cullinan Therapeutics (Nasdaq: CGEM), une soci茅t茅 biopharmaceutique sp茅cialis茅e dans les th茅rapies cibl茅es ind茅pendantes de la modalit茅, a annonc茅 sa participation 脿 deux prochaines conf茅rences pour investisseurs. Le PDG Nadim Ahmed et le directeur m茅dical Jeffrey Jones pr茅senteront au Cantor Global Healthcare Conference le 4 septembre 2025 脿 14h10 ET et au Morgan Stanley 23rd Annual Global Healthcare Conference le 10 septembre 2025 脿 8h30 ET.
Les deux pr茅sentations seront disponibles en webcast via le site des relations investisseurs de Cullinan.
Cullinan Therapeutics (Nasdaq: CGEM), ein biopharmazeutisches Unternehmen, das sich auf modalit盲tsunabh盲ngige, zielgerichtete Therapien spezialisiert hat, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angek眉ndigt. CEO Nadim Ahmed und CMO Jeffrey Jones werden am Cantor Global Healthcare Conference am 4. September 2025 um 14:10 Uhr ET und am Morgan Stanley 23rd Annual Global Healthcare Conference am 10. September 2025 um 8:30 Uhr ET pr盲sentieren.
Beide Pr盲sentationen werden als Webcasts 眉ber die Investor-Relations-Website von Cullinan verf眉gbar sein.
- None.
- None.
CAMBRIDGE, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- 听(狈补蝉诲补辩: CGEM; 鈥淐ullinan鈥�), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced its participation in the following upcoming investor conferences:
- Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 in New York, NY on Thursday, September 4, 2025, at 2:10 p.m. ET.
- Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY on September 10, 2025, at 8:30 a.m. ET.
Webcasts of the fireside chats will be available under the Events and Presentations section of the Company鈥檚 investor relations website at聽.
About Cullinan Therapeutics
鈥�(狈补蝉诲补辩: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients. Cullinan has strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both autoimmune diseases and cancer. Cullinan鈥檚 portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class. Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of autoimmune and cancer indications. We push conventional boundaries from candidate selection to differentiated therapeutic, applying rigorous go/no go criteria at each stage of development to fast-track only the most promising molecules to the clinic and, ultimately, commercialization. With deep scientific expertise, our teams exercise creativity and urgency to deliver on our promise to bring new therapeutic solutions to patients. Learn more about Cullinan at鈥�, and follow us on鈥�痑苍诲鈥�.
Contacts:
Investor Relations
Nick Smith
+1 401.241.3516
Media
Rose Weldon
+1 215.801.7644
FAQ
When is Cullinan Therapeutics (CGEM) presenting at the Cantor Global Healthcare Conference 2025?
When is Cullinan Therapeutics (CGEM) presenting at the Morgan Stanley Healthcare Conference 2025?
Who will represent Cullinan Therapeutics at the upcoming investor conferences?
How can investors access Cullinan Therapeutics' conference presentations?
